Q1 Earnings Forecast for MRVI Issued By KeyCorp

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – KeyCorp issued their Q1 2027 earnings per share (EPS) estimates for Maravai LifeSciences in a research note issued on Wednesday, November 11th. KeyCorp analyst P. Knight anticipates that the company will earn $0.00 per share for the quarter. KeyCorp has an “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share. KeyCorp also issued estimates for Maravai LifeSciences’ Q2 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.13) EPS.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Maravai LifeSciences had a negative return on equity of 12.44% and a negative net margin of 30.83%. The firm had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million.

MRVI has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. UBS Group lifted their price objective on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 9th. TD Cowen started coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a “buy” rating and a $9.00 price objective for the company. Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Maravai LifeSciences has a consensus rating of “Moderate Buy” and a consensus price target of $8.10.

Get Our Latest Report on Maravai LifeSciences

Maravai LifeSciences Price Performance

MRVI opened at $7.38 on Tuesday. The firm has a market capitalization of $1.92 billion, a PE ratio of -17.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.66 and a quick ratio of 3.35. The business’s 50-day moving average is $7.41 and its two-hundred day moving average is $5.48. Maravai LifeSciences has a 1 year low of $2.80 and a 1 year high of $9.42.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Renaissance Technologies LLC grew its stake in shares of Maravai LifeSciences by 0.9% during the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after acquiring an additional 39,600 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Maravai LifeSciences by 24.5% during the third quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company’s stock valued at $15,654,000 after acquiring an additional 402,371 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Maravai LifeSciences by 38.2% during the third quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock valued at $15,581,000 after acquiring an additional 562,593 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Maravai LifeSciences by 64.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after purchasing an additional 558,050 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Maravai LifeSciences in the 3rd quarter valued at approximately $5,259,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Read More

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.